3d Systems Corporation · NYSE:DDD

3d Systems — Merger or Acquisition (October 2021)

19 slides from 3d Systems's merger presentation, Oct 28, 2021

Slide 1: Volumetric Biotechnologies Acquisition
October 28, 2021 VOLUMETRIC BIOTECHNOLOGIES ACQUISITION Innovating Bioprinting Technologies and Transforming Patient Care ©2021 3D Systems, Inc. | All Rights Reserved.
Slide 2: Welcome and Participants
Welcome and Participants Dr. Jeffrey Graves President and Chief Executive Officer Jagtar Narula Executive VP and Chief Financial Officer Dr. Jordan Miller Co-Founder and President of Volumetric Biotechnologies To participate via phone, John Nypaver, Jr. please dial: VP, Treasurer and Investor Relati
Slide 3: Forward Looking Statements
Forward Looking Statements Certain statements made in this presentation that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncert
Slide 5: What is Regenerative Medicine?
What is Regenerative Medicine? The treatment of disease by repairing or replacing damaged tissues or organs using a patient’s own cells, thereby restoring functionality while avoiding risk of rejection. For organs, the process is: • Create scaffold using 3D printing, knows as “bioprinting” • Perfuse
Slide 6: Volumetric – Tying Together the Regenerative Medicine Strategy
Volumetric – Tying Together the Regenerative Medicine Strategy WHAT 3D SYSTEMS DOES TODAY WHAT VOLUMETRIC BRINGS  Organ printing  Exceptional tissue engineering and 3D Systems and United Therapeutics biological expertise +  Non-organ applications for human  Accelerated development and body comme
Slide 11: Vertical Integration in Organ Scaffolds
Vertical Integration in Organ Scaffolds Our team has demonstrated vertical integration across the organ fabrication pipeline 11 ©2021 3D Systems, Inc. | All Rights Reserved.
Slide 15: Financial Considerations
Financial Considerations • Upfront purchase price of $45 million, split roughly half between cash and 3D Systems common stock, subject to customary closing adjustments • Earnout opportunities (split roughly half between cash and stock) totaling up to an additional $355 million through December 31, 2
Slide 19: Presentation of Information
Presentation of Information 3D Systems reports is financial results in accordance with GAAP. To facilitate a better understanding of the impact that strategic acquisitions, non-recurring charges and certain non-cash expenses had on its financial results, management reviews certain non-GAAP measures,

3D Systems — Merger or Acquisition (October 2021) on 6ix

3d Systems — Merger or Acquisition (October 2021)

Slide 1: Volumetric Biotechnologies Acquisition

Slide 2: Welcome and Participants

Slide 3: Forward Looking Statements

Slide 4: Dr. Jeffrey Graves

Slide 5: What is Regenerative Medicine?

Slide 6: Volumetric – Tying Together the Regenerative Medicine Strategy

Slide 7: Dr. Jordan Miller

Slide 8: Recognized Leaders in Biomaterials and Bioprinting

Slide 9: ©2021 3D Systems, Inc. | All Rights Reserved.

Slide 10: Organ-Scale Diseases With No Cure

Slide 11: Vertical Integration in Organ Scaffolds

Slide 12: Venostent Arterialized Veins for Vascular Surgery

Slide 13: Dr. Jeffrey Graves

Slide 14: Jagtar Narula

Slide 15: Financial Considerations

Slide 16: Dr. Jeffrey Graves

Slide 17: Q&A Session

Slide 18: Thank You

Slide 19: Presentation of Information